Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy.

PloS one·2022

Same author

The Prediction of HER2-Targeted Treatment Response Using <sup>64</sup>Cu-Tetra-Azacyclododecanetetra-Acetic Acid (DOTA)-Trastuzumab PET/CT in Metastatic Breast Cancer: A Case Report.

Journal of breast cancer·2022

Same author

Targeted alpha immunotherapy of CD20-positive B-cell lymphoma model: dosimetry estimate of <sup>225</sup>Ac-DOTA-rituximab using <sup>64</sup>Cu-DOTA-rituximab.

Annals of nuclear medicine·2021

Same author

A preliminary clinical trial to evaluate <sup>64</sup>Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer.

EJNMMI research·2021

Same author

A microdose clinical trial to evaluate [<sup>18</sup>F]Florastamin as a positron emission tomography imaging agent in patients with prostate cancer.

European journal of nuclear medicine and molecular imaging·2020

Same author

Clinical Usefulness of 18F-FC119S Positron-Emission Tomography as an Auxiliary Diagnostic Method for Dementia: An Open-Label, Single-Dose, Evaluator-Blind Clinical Trial.

Journal of clinical neurology (Seoul, Korea)·2020

Search research articles

Related Experiment Video

Updated: Jan 6, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Clinical perspective on targeted alpha therapy using ²²⁵Ac.

Ilhan Lim^1,2,3

¹Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75 Nowon-ro, Gongneung dong, Nowon-gu, Seoul, 01812, Republic of Korea. ilhan@kcch.re.kr.

Annals of Nuclear Medicine

|October 9, 2025

Summary

Astatine-225 targeted alpha therapy shows promise for treating prostate cancer and neuroendocrine tumors with high efficacy and low toxicity. Further clinical research is needed to establish this advanced cancer treatment as a standard therapy.

Keywords:

225Ac Neuroendocrine tumor Prostate cancer Targeted alpha therapy (TAT)

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Experiment Videos

Last Updated: Jan 6, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Area of Science:

Oncology
Nuclear Medicine
Radiotherapy

Background:

Targeted alpha therapy using Astatine-225 (²²⁵Ac) offers high linear energy transfer (LET) and short particle range.
This approach has shown significant therapeutic benefits with minimal side effects in treating specific cancers.

Purpose of the Study:

To review current research on ²²⁵Ac targeted alpha therapy for prostate cancer and neuroendocrine tumors.
To explore advancements in protocols and expanded applications of this therapy for various cancers.

Main Methods:

Literature review of studies on ²²⁵Ac targeted alpha therapy.
Analysis of research focusing on treatment protocols and clinical outcomes.

Main Results:

²²⁵Ac therapy demonstrates outstanding therapeutic effects and minimal adverse effects in patients with prostate cancer and neuroendocrine tumors.
Research efforts are enhancing therapeutic outcomes and expanding applications to other tumor types.

Conclusions:

²²⁵Ac targeted alpha therapy is a highly effective treatment for certain cancers.
Additional clinical research is necessary to integrate ²²⁵Ac therapy into standard clinical practice.